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Abstract
Background: Based on sequence variation in the UL55 gene that encodes glycoprotein B (gB), human
cytomegalovirus (CMV) can be classified into four gB genotypes. Previous studies have suggested an association
between CMV gB genotype and clinical outcome in patients who underwent an allogeneic hematopoietic stem cell
transplant (HSCT). The goals of this study were identify patients with active infection caused by CMV in recipients of
HSCT; determine the prevalence of CMV genotypes in the study group; correlate genotype with CMV disease, acute
GVHD and overall survival.
Methods: The diagnosis of active CMV infection after allogeneic HSCT was detected by antigenemia (AGM) and/or
nested-PCR (N-PCR). Positive samples from patients with active CMV infection were submitted to genotyping using
N-PCR to amplify a region of UL55, followed by restriction analysis based on HinfI and RsaI digestion. Real-time PCR
(qPCR) was used to determine the viral load during active CMV infection and antiviral treatment.
Results: Sixty-three allogeneic HSCT recipients were prospectively evaluated; 49/63 (78%) patients were infected
with CMV genotypes – gB1 19/49 (39%), gB2 17/49 (35%), gB3 3/49 (6%), gB4 7/49 (14%) – and 3 (6%) had mixed
CMV genotypes (gB1 + gB3, gB1 + gB4 and gB2 + gB4). Characterized by gastrointestinal disease, CMV disease
occurred in 3/49 (6.1%) patients, who had CMV gB3 genotype. These gB3 genotype patients presented an
increasing AGM number, mean 125 (± 250) (P = 0.70), and qPCR copies/ml, mean 37938 (SD ± 50542) (P = 0.03),
during antiviral treatment, when compared with other CMV genotypes. According to CMV genotypes, stratified
overall survival was 55% for gB1, 43% for gB2; 0% for gB3 and 57% for gB4 (P = 0.03).
Conclusions: One of the restrictions of the presented study was the low number of CMV gB sub-cohorts).
However, we demonstrated that the frequency of active CMV infection in this HSCT population was high, and the
most prevalent genotype in these patients with active CMV infection was gB1 and gB2 genotype (74%). In Brazil,
HSCT recipients seem to carry mainly gB1 and gB2 CMV genotype.
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Background
Cytomegalovirus (CMV) remains the most important
cause of serious viral infections in allogeneic hema-
topoietic stem cell transplant (HSCT) recipients [1].
CMV glycoprotein B (gB) is the major CMV envelope
glycoprotein and it is encoded by UL55 gene. CMV gB
has been implicated in host cell entry, cell-to-cell viral
transmission and fusion of infected cells [2-4]. Chou and
Dennison (1991) devised a method of CMV genotyping
based on UL55 gene nucleotide sequence that encodes a
variable region encompassing the protease cleavage site.
They found that there were HinfI and RsaI restriction
sites between nucleotides 1344 and 1440. Amplification
of this region, using polymerase chain reaction (PCR)
followed by restriction analysis, demonstrated the exis-
tence of four different gB genotypes [5]. Since gB has
been implicated in host cell penetration, it is possible
that four types differ with respect to tissue tropism and
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virulence. Many studies have attempted to find a correl-
ation between gB genotype and the occurrence of CMV-
associated disease in immunocompromised patients;
however, it remains unclear whether certain gB geno-
types are associated with an increased frequency of
disease [6]. There are few references about functional
differences that may exist among various CMV strains. It
was reported that the existence of CMV variants played
an important role in the pathogenesis of diseases, as
these variants affected several genes that might be
responsible for different diseases related to active CMV
infection [7-10]. Recently, comparative sequence studies
have been used to define the extent of interstrain vari-
ation in selected coding regions of the CMV genome.
Clinical CMV isolates were found to adopt one of four
gB sequence configurations at certain variable loci, and a
genotyping scheme was proposed [11-13]. Although gB
genotypes display significant amino acid variations in
their variable domains, including changes that affect
glycosylation sites, the functional consequences of these
variations have not yet been explored [14-24].
This study aimed to prospectively analyze gB gene of
CMV in allogeneic hematopoietic stem cell transplant
(HSCT) recipients with human active CMV infection to
determine the distribution of gB genotypes and their




This study comprised 63 adult patients with malignant
and nonmalignant hematological diseases, who under-
went a myeloablative or nonmyeloablative allogeneic
HSCT at the Hematopoietic Stem Cell Transplantation
Unit of the University of Campinas Teaching Hospital,
with related or not related HLA identical donors and
graft source from bone marrow or peripheral blood. The
blood products used were neither screened for CMV
antibody nor filtered to depleted leukocytes, although all
had been irradiated. The conditioning regimens and
GVHD prophylaxis were selected according to ongoing
protocols at the University Hospital. These patients were
prospectively monitored for active CMV infection from
March 2007 to May 2010, using antigenemia (AGM)
assay, nested-polymerase chain reaction (N-PCR) in
leukocytes, and real-time polymerase chain reaction
(qPCR). Patients with active CMV infection results were
treated with preemptive ganciclovir. CMV genotypes of
all positive patients were obtained by N-PCR and
confirmed by sequencing, using primers from the glyco-
protein B (gB) region of CMV (UL55) and restriction
enzyme analysis (RFLP) with HinfI and RsaI enzymes.
Real-time polymerase chain reaction (qPCR) assay was
used to quantify the CMV load during active CMV
infection and antiviral preemptive treatment. The proto-
col was designed in accordance with the requirements for
research involving human subjects in Brazil and approved
by the Institutional Review Board. Informed consent was
obtained from all patients. Clinical characteristics of the
study subjects are summarized in Table 1.
The study was approved by the National Research Ethics
(CONEP) of Brazil (680/2006).
Definitions
Active CMV infection was defined based on at least one
of the following criteria: [1] one or more positive cells in
the AGM assay, and [2] two or more consecutive posi-
tive N-PCR results. For the diagnosis of CMV disease,
the active infection had to be accompanied by clinical
symptoms and histopathological identification of CMV
[25]. Recurrence of CMV infection was defined as active
CMV infection occurring after negative N-PCR and/or
AGM assays, following treatment of the initial episode
of infection. Late active CMV infections and diseases
were defined as those occurring more than 100 days
after transplant.
Antigenemia assay
AGM assay was done at least once a week after engraft-
ment, according to Bonon et al., 2005, with some modifi-
cations. EDTA-treated blood samples were fractionated by
erythrocyte lyses. Granulocytes were then centrifuged to
prepare cytospin slides (2 × 105 granulocytes per slide).
After air-drying and fixing the slides in formaldehyde, they
were immunostained using the well-defined C10/C11
antibody cocktail to detect the CMV lower matrix phos-
phoprotein (pp65), an early antigen in virus replication,
which is abundantly present in antigen-positive poly-
morphonuclear cells. The CMV Brite™ Turbo Kit (Iq Pro-
ducts) is a rapid new version of the first FDA registered
immunofluorescence antigenemia kit for in vitro CMV
diagnosis. Slides weremade in duplicate [26].
Nested polymerase chain reaction (N-PCR)
CMV DNA in blood specimens was detected by nested
PCR using the primers described by Demmler et al. and
Shibata et al. (1988). Briefly, leukocytes remaining from
the CMV antigenemia assay were lysed and the DNA
was precipitated. The primers were selected from the
MIE region of CMV-AD169. The size of the PCR ampli-
fication products was 159 base pairs. The same protocol
was used to amplify the human b-globin gene sequence
to guarantee the quality of the extracted DNA [27,28].
Cytomegalovirus viral load assay
Real-time PCR
PCR primer and probe sequences were selected from the
US17 region of CMV AD169. The real-time protocol
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was according to Peres et al., 2010. The forward and re-
verse CMV primers were 5′ GAAGGTGCAGGTGCCC
TG 3′ and 5′ GTGTCGACGAACGACGTACG 3′, re-
spectively. The Taq Man probe selected between both
primers was fluorescence labeled with 6-carboxyfluorescein
at the 5′ end as the reporter dye and 6- carboxytetrame-
thylrhodamine at the 3′ end as the quencher (5′FAM
ACGGTGCTGTAGACCCGCATACAAATAMRA3′).
A search of databases indicated that neither the
primers nor the probes shared significant homology with
any known nucleotide sequence except of CMV. The
real-time PCR was performed with a mixture containing:
3 mM MgCl2; 10 μM dATP, dCTP, dGTP, dTTP; 5 U/μl
of Platinum Taq (Invitrogen), 60 ng DNA templates,
150 nM of forward and reverse primers (CMVUS17F-
CMVUS17R for CMV detection) and 2 μM of the spe-
cific Taq Man CMV probe (PE Applied Biosystems). The
single PCR was performed in 96-well microliter plates
under the following conditions: 1 cycle at 50°C for 2 -
minutes, 95°C for 10 minutes and 45 cycles at 95°C for
15 seconds and 60°C for 1 minute. The ß-actin gene
amplification was performed under the same PCR condi-
tions described above for the reaction control, using
2 μM ß-actin probe (FAM™ Probe), 3 μM ß-actin for-
ward primer, and 3 μM ß-actin reverse primer (TaqMan®
ß-actin detection reagents - Applied Biosystems) [29].
Amplification of gB gene by nested-PCR
Oligonucleotide primers used for PCR amplification
were chosen in a region of high sequence variability in
the CMV gB gene, as previously published by Chou and
Dennison (1991), and were synthesized commercially
(Invitrogen, by Life Technologies, Brazil). The first and
the second rounds of amplification were carried out in a
total volume of 50 μl, using 200 ng DNA extract (1st)
and 1 μl PCR product (2nd) and 49 μl PCR mix (10 mM
Tris pH 8.3, 50 mM KCl, 2 mM MgCl2, 200 mM of each
dNTPs, 1.25 U of recombinant Taq DNA polymerase
and 0.4 mM of each primer (Invitrogen, by Life Techno-
logies, Brazil). After amplification, 5 μl of the amplified
product were electrophoresed on 2% agarose gel (Gibco-
BRL, Grand Island, NY) containing ethidium bromide, and
the gel was photographed under UV illumination. The
AD169 strain was used as a positive control; an uninfected
DNA sample or water was used as a negative control [5].
CMV gB genotyping with PCR-RFLP analysis and
sequence analyses
Approximately 10 μl of nested PCR product were di-
gested at 37°C overnight, using 1 U of the restriction
enzymes, Rsa I and Hinf I (Gibco-BRL). Sequences were
analyzed on a 2% agarose 1000 gel (Gibco-BRL). The
four types of gB were distinguished by their different
patterns of fragment lengths, as described [5].
Table 1 Patient and transplant characteristics
Characteristics n = 63
Patient age, median (range), y 42 (16–65)
Diagnosis at transplant, no. (%)
Malignant diseases
Acute myeloid leukemia 23 (36.5%)
Chronic myeloid leukemia 9 (14.3%)
Acute lymphoblastic leukemia 9 (14.3%)
Chronic lymphocytic leukemia 4 (6.3%)
Multiple myeloma 2 (3.2%)
Non-Hodgkin lymphoma 3 (4.8%)
Hodgkin lymphoma 2 (3.2%)
Myelodysplastic syndrome 4 (6.3%)
Non-malignant diseases
Severe aplastic anemia 4 (6.3%)
Paroxysmal nocturnal hemoglobinuria 3 (4.8%)
Donor age, median (range), y 39 (6–65)





Donor type, no. (%)
HLA-identical related 61 (96.8%)
HLA-matched unrelated 2 (3.2%)
Conditioning regimen, no. (%)
High dose 46 (73%)
Low dose 17 (27%)
Source of stem cells, no. (%)
Bone marrow 23 (36.5%)
Mobilized blood 40 (63.5%)
GVHD prophylaxis, no. (%)
Cyclosporine plus methotrexate 49 (77.7%)
Cyclosporine plus mycophenolate mofetil 14 (22.3%)
Acute GVHD, no. (%) 17 (27%)
Grade 0-I 46 (73%)
Grade II-IV 17 (27%)
Donor/recipient CMV serologic status, nº (%)
IgG +/IgG+ 55 (87.2%)
IgG +/IgG - 3 (4.8%)
IgG -/IgG - 2 (3.2%)
IgG-/igG+ 2 (3.2%)
Not determined 1 (1.6%)
GVDH graft-versus-host disease, CMV cytomegalovirus.
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To determine the sequences of the CMV gB genotype
samples, the PCR products were purified using the PCR
purification kit (Quiagen) and subcloned into the pGEM-
T vector (Promega, Madison, WI, USA). Sequences were
obtained using the ABI 310 genetic analyser (Applied
Biosystems, Bedford, MA, USA) with proper primers, and
they were aligned with known CMV variants in GenBank
afterward. The sequences of gB1, gB2, gB3 and gB4 were
very similar to GenBank M60927, M60931, M60930 and
M60926 respectively.
Statistical analysis
The descriptive analysis summarized patient sociodemo-
graphic characteristics, as well as transplant, GVHD and
CMVserologic status of donors and receptors. The Fisher’s
and Kruskal-Wallis tests were applied for categorical
and continuous variables, respectively. The Kaplan-Meier
method was used to estimate overall survival. Stratified
overall survival, according to CMV genotypes, was com-
pared with the log-rank test. Death by any cause was con-
sidered as event. The gB1 + gB3 mixture was clustered into
genotype gB3 for statistical purpose, since these strains had
the same behavior in the study.
The other two mixtures detected, gB1 + gB4 and gB2 +
gB4, were not grouped, as they did not identify any
pattern of behavior. The p-value < 0.05 was considered
significant. The statistical analyses were performed using
the software SPSS 14 (Statistical Package for Social
Sciences).
Results
Among the 63 patients, 49 (78%) had active CMV infection
detected by AGM and/or N-PCR tests. Active CMV infec-
tion occurred within a median time of 38 days (1–150)
after the transplant. The median time to detect active
CMV infection by AGM and N-PCR was 46 (14–150) and
34 days (1–140), respectively. The incidence of active
CMV infections is summarized in Table 2.
CMV gB genotype
Forty-nine patients with active CMV infection were sub-
mitted to CMV genotyping using RFLP. Nineteen out of
49 (39%) recipients had gB1 genotype; 17 out of 49 (35%),
gB2; 3 out of 49 (6%), gB3; and 7 out of 49 (14%), gB4.
There were three patients (6%) who had a combination of
two different CMV genotypes (gB1 + gB3, gB1+ gB4 and
gB2 + gB4).
Eight samples (two with gB1, two with gB2, two with
gB3 and two with gB4) and three mixed CMV genotype
samples were sequenced. The patients’ CMV sequences
were 98-99% identical to CMV sequences in GenBank
when compared.
CMV disease, acute GVHD and gB genotype
Among the 49 patients who had active CMV infection,
three (6%) developed CMV disease manifested as gastro-
intestinal disease, two had gB3 and one had a mixture of
gB1 + gB3 strains.
The active CMV infection recurrence detected by
HCMV antigenemia and/or nested PCR occurred in 9 out
of 49 (18%) patients within a median of 92 days (61–138),
with the same infecting strain caused by the first active
CMV infection. The recurrence occurred in 1 out of 9
(11%) cases with gB1, in 1 out of 9 (11%) with gB2, in 3
out of 9 (33%) with gB3, and in 4 out of 9 (44%) with gB4.
Seventeen out of 49 (35%) patients with CMV active
infection developed grade II-IV acute GVHD. Among
the patients with acute GVHD, 12 out of 17 (70.6%) had
acute GVHD before diagnosis of active CMV infection;
however, 5 out of 17 (29.4%) patients had active CMV
infection before acute GVHD. Diagnosis of active CMV
infection occurred within a median of 20 days [6-35] after
diagnosis of acute GVHD, and acute GVHD occurred
within a median of 45 days (27–59) after active CMV
infection. The frequency of II-IV acute GVHD, according
to CMV gB genotype, showed that 8 out of 19 gB1 pa-
tients (42%), 1 out of 17 gB2 patients (6%), 3 out of 7 gB4
patients (43%) had aGVHD, and all 4 gB3 patients, includ-
ing the mixture gB1 + gB3, had aGVHD (P = 0.008).
CMV DNA load at onset of active CMV infection and
during preemptive treatment monitoring
At the active CMV infection onset, gB3 genotype pre-
sented the highest number of AGM-positive, mean 251
(SD ± 499), and gB2 the highest qPCR copies/ml, mean
1733 (SD ± 6272). However, the difference between the
four genotypes for either AGM or qPCR was not signifi-
cant (AGM – p-value = 0.73; qPCR - p-value = 0.13).
These results are summarized in Table 3.
In spite of preemptive treatment for active CMV infec-
tion, three out of four gB3 patients developed gastro-
intestinal disease. In two out of those three patients,
CMV replication occurred after onset of grade II-IV
acute GVHD. Interesting, during preemptive treatment,
these gB3 genotype patients presented an increasing
AGM number, mean 125 (± 250) (p = 0.70), and qPCR
Table 2 Incidence of active CMV infection
Patients n = 63
Positive N-PCR and/or AGM, n (%) 49 (78%)
Median time, days (range) 38 (1–150)
Positive N-PCR, n (%) 49 (78%)
Median time, days (range) 34 (1–140)
Positive AGM, n (%) 37 (58.7%)
Median time, days (range) 46 (14–150)
N-PCR nested polymerase chain reaction, AGM antigenemia.
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copies/ml, mean 37938 (SD ± 50542), when compared
with other CMV genotypes (p = 0.03). These results are
presented in Table 4 and Figure 1.
Overall survival and CMV gB genotype
Among the 49 patients with active CMV infection, 25
(51%) died. The distribution of causes of death were as
follows: relapse, 10 out of 25 (40%); bacterial or fungal
infection, 10 out of 25 (40%); GVHD, 2 out of 25 (8%);
cardiac toxicity, 1 out of 25 (4%); pulmonary hemorrhage,
1 out of 25 (4%); CMV disease, 1 out of 25 (4%).
After a median follow-up of 17 months [1-52], the
overall survival for patients with active CMV infection
was 45% (95% CI 39-61%); whereas the stratified overall
survival, according to CMV genotypes, was 55% for gB1,
43% for gB2; 0% for gB3 and 57% for gB4 (p = 0.03), as
shown in Figures 2 and 3.
Discussion
In this cohort of Brazilians patients with active CMV
infection, the most frequent genotypes were gB1 and
gB2 (74%). Moreover, all patients who had CMV gastro-
intestinal disease, higher viral load during preemptive
antiviral treatment, acute GVHD grade II-IV and worse
survival were gB3 genotype.
The high incidence of active CMV infection detected
either by N-PCR or AGM in our population was com-
parable to prior reports and they were equally effective
for diagnosis of active infection and disease [26,30-32].
Although the proportion of CMV seronegative donors or
recipients has been small, almost all positive N-PCR and
AGM results were from CMV seropositive patients.
According to previously described CMV envelope glyco-
protein genotypes, we were able to confirm that CMV gB
genotyping could reliably identify one of four established
gB genotypes, using two restriction endonucleases – HinfI
and RSAI – to digest the PCR-amplified variable region of
UL55, encoding the protease cleavage site [5,33]. GB1 and
gB2 were the most frequent genotypes in this study, and
they occurred in similar proportions (39% and 35%, re-
spectively). These results are in line with other studies, in-
cluding one from our group performed in a Brazilian
pediatric renal and hematopoietic stem cell transplant-
ation cohort [7,34-37], but not with a report from Chinese
HSCT patients, where gB1 and gB3 were the prevalent
genotypes [38,39]. Furthermore, in our population, the
Table 3 Results of AGM and viral load by qPCR at active CMV infection and during preemptive treatment monitoring
Genotypes Median Range Mean SD Mean* SD
gB1 AGM (n cells) 3 0-38 8 ± 12 – –
qPCR (copies/ml) 92 15-804 388 ± 864 2.05 ± 0.68
gB2 AGM (n cells) 3 0-10 3 ± 3 – –
qPCR (copies/ml) 23 3-26012 1733 ± 6272 1.72 ± 1.07
gB3 AGM (n cells) 2 1-1000 251 ± 499 – –
qPCR (copies/ml) 12 3-753 195 ± 372 1.37 ± 1.05
gB4 AGM (n cells) 1 0-70 11 ± 26 – –
qPCR (copies/ml) 351 13-2283 675 ± 892 2.32 ± 0.84
AGM antigenemia, qPCR real-time polymerase chain reaction.
*Mean qPCR in logarithm base 10; n = number of pp65 CMV positive cells/2 × 105; SD = standard deviation; AGM – p-value = 0.73; qPCR - p-value = 0.13
(kruskal-WallisTest).
Table 4 Results of AGM and viral load by qPCR in the monitoring of preemptive antiviral treatment stratified by
genotypes
Genotypes Median Range Mean SD Mean* SD
gB1 AGM (n cells) 0 0-200 12 ± 46 – –
qPCR (copies/ml) 261 15-8358 1247 ± 2352 2.51 ± 0.76
gB2 AGM (n cells) 0 0-500 63 ± 165 – –
qPCR (copies/ml) 359 5-26012 4088 ± 8537 2.45 ± 1.16
gB3 AGM (n cells) 0 0-500 125 ± 250 – –
qPCR (copies/ml) 20751 115-110136 37938 ± 50542 3.86 ± 1.31
gB4 AGM (n cells) 0 0-7 1 ± 3 – –
qPCR (copies/ml) 4690 46-73084 15758 ± 26024 3.41 ± 1.23
AGM antigenemia, qPCR real-time polymerase chain reaction.
*Mean qPCR transformed in logarithmic base 10; n = number of pp65 CMV positive cells/2 × 105; SD = standard deviation. Antigenemia – P-value = 0.70;
qPCR - P-value = 0.03 (kruskal-WallisTest).
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proportion of mixed genotypes was rare (6%), that is com-
parable to recent reports which showed ranges from 5% to
25% [6,38,40].
CMV gB genotype may be an important determinant
of viral virulence because gB has been implicated in sev-
eral essential steps in CMV pathogenesis, such as virus
entry, cell fusion, and cell-to-cell spread. The virulence
of different CMV strains may be an important factor in
the occurrence of CMV disease because of genetic vari-
ation in genes that are involved in host cell penetration,
tissue tropism, or replication, and polymorphism in the
viral genome may play an important role [40-42].
Outcomes of different CMV genotypes with clinical
manifestations are conflicting. CMV gB3 and gB4 were
reported to be associated with myelosuppression in HSCT
patients [35], gB3 with high incidence of pneumonitis [38],
and gB1 with invasive disease in solid organ transplant-
ation [36,38]. A recent Brazilian study involving AIDS
patients demonstrated that gB2 genotype was associated
with worse prognosis [43]. In prior studies, mixed CMV
genotypes were observed to be associated with a high
prevalence of CMV disease in solid-organ transplant pa-
tients [6,44,45], but in our study we did not find these
results.
Neither cases of myelossupression and pneumonitis,
nor a high prevalence of CMV disease in mixed CMV
genotypes were seen in our data, but intriguing all cases
of CMV disease were associated with the gastrointestinal
tract, and all of them had genotype gB3. Hence, gB3
genotype might confer a specific virulence advantage for
that genotype in our cohort. Although some associations
have been described so far between a certain virus
subtype and the development of individual disease these







Figure 1 Antigenemia and viral load by qPCR in the monitoring of preemptive antiviral treatment stratified by genotypes.
Figure 2 Overall survival. Figure 3 Overall survival by genotype.
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background of CMV, by the large variety of individual
host-virus relations and by differences in the geographic
or demographic subtype distribution [46].
Acute GVHD and CMV replication are pathogenetically
associated. In this report, most patients had GVHD before
the onset of CMV infection, confirming what several stu-
dies have already shown that acute GVHD and its treat-
ment put patients at risk for CMV replication [43,47-49].
In contrast, the role of CMV replication as a cause of
acute GVHD is controversial. One recent small study
found no effect of CMV replication on subsequent devel-
opment of acute GVHD [50]. Others demonstrated the
reciprocal finding that patients are at significant risk of de-
veloping acute GVHD during CMV replication [43,51].
Torok-Storb et al. [35] reported that CMV gB3 was as-
sociated with a reduced risk of GVHD in HSCT patients.
Wu et al. [38] failed to demonstrate an association of B
genotypes with GVHD. We found a different distribu-
tion of II-IV acute GVHD according to gB genotypes,
and all gB3 genotypes were involved with acute GVHD,
highlighting a possible association of that genotype with
acute GVHD.
We observed that the mean load viral was higher in gB2
at the diagnosis; however, during the preemptive antiviral
treatment, the viral load detected, either by qPCR and
AGM, showed an increase in gB3 genotype. Clearly, geno-
type gB3 showed a different behavior when compared with
other genotypes, leading to believe that this might be asso-
ciated with a more severe and uncontrolled infection that
caused all cases of gB3 gastrointestinal CMV disease and a
worse survival in our population.
Perhaps, not gB3 genotype per se but its low frequency
in the patient’s cohort may be associated with bad out-
come of the CMV infection. If this genotype is rare in
this region, higher is the probability of primo infection
in this population during the transplantation, that is as-
sociated with insufficient or delayed immune response,
prolonged high level of virus replication and higher risk
of CMV disease and related complications.
Conclusion
One of the restrictions of the presented study was the low
number of CMV gB sub- cohorts). However, we demon-
strated that the frequency of active CMV infection in this
HSCT population was high and the most prevalent geno-
type in these patients with active CMV infection was gB1
and gB2 genotype (74%). In Brazil, HSCT recipients seem
to carry mainly gB1 and gB2 CMV genotype.
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